Tiffany Garbutt, PhD
Tiffany earned her PhD in Genetics from North Carolina State University, where she explored the effect of genetic background on the ability to derive induced pluripotent stem cells. She completed her postdoctoral training at the University of North Carolina at Chapel Hill, specializing in the development of translational approaches to direct cardiac reprogramming and understanding the mechanisms of cardiomyocyte maturation. She has written for multiple medical, nonprofit, and academic peer-reviewed outlets. In March 2020, Tiffany joined LabX Media Group as an assistant science editor for The Scientist. She began working with Drug Discovery News in October 2020.
Articles by Tiffany Garbutt, PhD
Plants offer several unique advantages for accelerated vaccine production.
Amongst a plethora of stem cells, which cell type should scientists choose?
| 4 min read
Scientists and clinicians discussed their solutions for overcoming the challenge of getting past the blood-brain barrier in DDN’s first seminar.
Scientists delve into the spatial context of cancer biology, opening new treatment avenues.
Bats, pigs, and pangolins – oh my! The COVID-19 pandemic highlighted the consequences of viral spillover from animals, but it is not the first time in history that an animal virus has spurred disease in humans.
| 2 min read
Scientists leverage the natural ability of antibodies to cross the blood-brain barrier and target proteins implicated in neurodegenerative disease.
| 1 min read
New directions for cell therapy extend beyond T cells and cancer treatment.
| 4 min read
Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.
| 5 min read
A naturally occurring nanoparticle yields a new type of vaccine that offers broad-acting protection against emerging SARS-CoV-2 variants. With further development, the approach may lead to a pan-coronavirus vaccine.
| 1 min read
Discover leading immunotherapy targets in the the drug development pipeline.
| 9 min read
What happens after the vaccine is injected into your arm?
| 1 min read
Infectious diseases alter the traditional vaccine pipeline and spawn new approaches to antibody research and vaccine development.
